Home > Companies > Portfolio Companies > Thermalin Diabetes, LLC

Portfolio Companies

Thermalin Diabetes, LLC

www.thermalin.com

Thermalin Diabetes is developing clinically-superior, second generation insulin analogs for the rapidly growing $12 billion insulin market.

Thermalin's patent pending compounds include rapid-, intermediate- and long-acting analogs. With patents expiring on existing analogs in the next three to four years, Thermalin looks to form partnerships with large pharmaceutical companies that wish to market superior, next generation insulin therapies.

Initial JumpStart Investment: March 2010

For more information on Thermalin Diabetes, contact: Lynn-Ann Gries

News

Thermalin Diabetes gets $4.5M NIH grant for next-generation insulin
Wednesday, April 25, 2012

Excerpt of story provided by MedCity News

Written by Brandon Glenn

Stories

Big Market, Bigger Mission
Tuesday, January 25, 2011

In an interview with JumpStart, Richard Berenson, CEO of Thermalin Diabetes, talked about how his company's success could change the lives of millions and put him in a position to help other entrepreneurs. Read Richard's story.